Evidence map›Paper›PMID 42178218›Full record

ArticlePhytotherapy research : PTR2026

Berberine Improved the Therapeutic Efficacy of UC-MSCs for DSS-Induced Colitis via Aerobic Glycolysis.

Mengye Wu, Cuiping Li, Jianqi Feng, Xiaolu Guo, Rui Fang, Qinghai Lian, Xiaoran Zhang, Jianping Ma, Yanling Li, Shujuan Xie and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mengye WuThe Biotherapy Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Cuiping LiThe Biotherapy Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Jianqi FengCenter for Stem Cells Translational Medicine, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Xiaolu GuoCenter for Stem Cells Translational Medicine, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Rui FangCenter for Stem Cells Translational Medicine, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Qinghai LianCell-Gene Therapy Translational Medicine Research Centre, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Xiaoran ZhangCenter for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Jianping MaCenter for Stem Cells Translational Medicine, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.
Yanling LiThe Biotherapy Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Shujuan XieThe Biotherapy Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Haiyan ZhangDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Yanwen PengThe Biotherapy Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0002-3760-7397

Funding

Fundamental and Applied Basic Research of Guangzhou City University (Institution) Projects 202201020461Guangzhou Science and Technology Plan Projects 202102020104Guangzhou Science and Technology Plan Projects 202206080002Guangzhou Science and Technology Plan Projects 2023A04J2063Key Research and Development Program of Guangdong Province 2023B1111050006Natural Science Foundation of Guangdong Province 2021A1515010477Natural Science Foundation of Guangdong Province 2022A1515010430Natural Science Foundation of Guangdong Province 2022A1515011413Natural Science Foundation of Guangdong Province 2022A1515012452Sanming Project of Medicine in Shenzhen Nanshan SZSM202103012Shenzhen Nanshan District Science and Technology Program NS2022023The National Natural Science Foundation of China 82170216The National Natural Science Foundation of China 82170540
6 · The paper itself

Abstract

The global prevalence of inflammatory bowel disease (IBD) continues increasing, but effective targeted treatments remain elusive. Recently, mesenchymal stem cells (MSCs) have emerged as a promising candidate for IBD treatment, with energy metabolism playing a critical role. Berberine (BBR), a natural extract from Berberidaceae plants, has been shown to modulate various cell functions by reprogramming metabolism in immune-related diseases. This study aims to investigate the influence of BBR on the therapeutic effectiveness of MSCs in colitis. Using the colitis mice model, we compared the therapeutic effects of BBR treated MSCs (MSC

Indexed as

BerberineColitisGlycolysisMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsDextran SulfateDisease Models, AnimalGlucose Transporter Type 1MaleMiceMice, Inbred C57BLSignal TransductionBerberineDextran SulfateGlucose Transporter Type 1AMPK pathwayberberine (BBR)glucose transporter 1 (GLUT1)glycolysisinflammatory bowel disease (IBD)mesenchymal stem cells (MSCs)

Identifiers

PMID42178218
PMCPMC13436295

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.